No change in calculated creatinine clearance after tenofovir initiation among Thai patients
Open Access
- 21 March 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 59 (5) , 1034-1037
- https://doi.org/10.1093/jac/dkm064
Abstract
Thai patients have a lower average body weight than patients from western Europe or the USA. Tenofovir is largely prescribed at the standard dosage of 300 mg once daily: therefore, the per kilogram dose is higher in Thailand than in the USA. We asked the question whether this higher per kilogram dose was associated with more nephrotoxicity. Thai patients from the Staccato trial were treated with tenofovir/lamivudine combined with ritonavir-boosted saquinavir. Creatinine values were measured before the start of tenofovir and then every 12 weeks. Renal function was assessed using the Cockcroft–Gault formula and the MDRD formula. To compare CLCR before and after tenofovir, the t-paired or Wilcoxon signed rank tests were used. One-way analysis of variance and Spearman's correlation coefficient were used to study CLCR longitudinally. CLCR remained stable after a median of 21 weeks on tenofovir (difference of +1.06 mL/min; 95% CI −2.7–4.8, P = 0.58), even among patients with underlying diseases. The mean CLCR remained stable across time (P = 0.17). We did not find renal dysfunction on tenofovir among Thai patients included in the Staccato trial. Tenofovir could be safely prescribed at a standard dosage of 300 mg once daily in the Thai population.Keywords
This publication has 12 references indexed in Scilit:
- CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trialThe Lancet, 2006
- Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIVNew England Journal of Medicine, 2006
- Minor changes in calculated creatinine clearance and anion‐gap are associated with tenofovir disoproxil fumarate‐containing highly active antiretroviral therapyHIV Medicine, 2006
- Tenofovir-Associated Acute and Chronic Kidney Disease: A Case of Multiple Drug InteractionsClinical Infectious Diseases, 2006
- Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patientsJournal of Antimicrobial Chemotherapy, 2005
- Incidence of and risk factors for tenofovir‐induced nephrotoxicity: a retrospective cohort studyHIV Medicine, 2005
- Changes in Renal Function Associated with Tenofovir Disoproxil Fumarate Treatment, Compared with Nucleoside Reverse‐Transcriptase Inhibitor TreatmentClinical Infectious Diseases, 2005
- Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre studyNephrology Dialysis Transplantation, 2005
- Renal safety of tenofovir in HIV treatment-experienced patientsAIDS, 2004
- A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction EquationAnnals of Internal Medicine, 1999